How can my patient safely discontinue escitalopram (Lexapro) and propranolol?

Safe Discontinuation of Lexapro (Escitalopram) and Propranolol

Both medications require gradual tapering to prevent withdrawal syndromes—never discontinue abruptly, as this can cause significant morbidity including cardiovascular complications with propranolol and distressing neuropsychiatric symptoms with escitalopram.

Propranolol Discontinuation

Taper propranolol gradually over at least 2 weeks, reducing to a small maintenance dose (30 mg daily) for 2 weeks before complete cessation 12. The FDA label explicitly warns against abrupt discontinuation due to risk of exacerbation of angina and myocardial infarction 1.

Propranolol Tapering Protocol:

• Reduce dose by 25-50% every 3-7 days until reaching 30 mg daily
• Maintain 30 mg daily for 2 weeks before final discontinuation 2
• This prolonged small-dose approach prevents:
  • Enhanced beta-adrenergic cardiac sensitivity
  • Rebound hypertension and tachycardia
  • Elevated plasma catecholamines
  • Withdrawal symptoms 2

Critical Monitoring During Propranolol Taper:

• Blood pressure and heart rate at each dose reduction
• Angina symptoms (even in patients without known coronary disease, as it may be occult) 1
• If angina worsens, reinstitute propranolol and slow the taper 1

Common pitfall: Simple serial dose reduction over 6-9 days is insufficient and fails to prevent cardiac hypersensitivity in most patients 2. The prolonged small-dose strategy is superior.

---

Lexapro (Escitalopram) Discontinuation

Taper escitalopram very slowly over weeks to months, using progressively smaller dose reductions as you approach zero 334. The FDA label mandates discussing tapering regimens with patients and warns that adverse reactions occur with discontinuation 33.

Escitalopram Tapering Protocol:

For Low-Risk Patients (short duration of use, lower doses):

• Reduce by 25-50% every 2 weeks
• Example: 20 mg → 10 mg (2 weeks) → 5 mg (2 weeks) → stop 5

For High-Risk Patients (higher doses, longer duration >6 months, prior withdrawal difficulties):

• Use hyperbolic dose reductions (each reduction is 10% of the previous dose, not the starting dose) 45
• Taper over months, potentially reaching doses as low as 1 mg before cessation 5
• Example: 20 mg → 18 mg → 16 mg → 14 mg → 12 mg → 10 mg → 9 mg → 8 mg → 7 mg → 6 mg → 5 mg → 4 mg → 3 mg → 2 mg → 1 mg → stop
• Each step may require 2-4 weeks 4
• Consider liquid formulations or dissolving tablets for precise micro-dosing 45

Risk Factors for Severe Withdrawal:

• Higher doses and plasma concentrations are significantly associated with discontinuation syndrome 6
• At least 50% of patients experience withdrawal symptoms 4
• Common symptoms: dizziness (44%), muscle tension (44%), chills (44%), confusion (40%), amnesia (28%), crying (28%) 6

Monitoring During Escitalopram Taper:

• Follow-up every 2-4 weeks during active tapering 4
• Distinguish withdrawal symptoms from relapse:
  • Withdrawal: Occurs within days of dose reduction, includes physical symptoms (dizziness, paresthesias, flu-like symptoms)
  • Relapse: Occurs weeks later, primarily mood/anxiety symptoms matching original presentation
• Pause or reverse taper if severe symptoms emerge 4

Critical pitfall: Abrupt discontinuation or rapid tapers cause discontinuation syndrome in the majority of patients 46. Very slow tapering is recommended for all patients 6.

---

Sequencing the Discontinuation

Taper propranolol first (2-4 week process), then begin escitalopram taper once propranolol is fully discontinued. This prevents:

• Overlapping withdrawal syndromes that complicate symptom attribution
• Cardiovascular instability from propranolol withdrawal being masked by escitalopram's effects
• The longer escitalopram taper requiring sustained attention without concurrent medication changes

---

Patient Education and Shared Decision-Making

Inform your patient that:

• Withdrawal symptoms are common but manageable with proper tapering 4
• The process may take months, not weeks 45
• Symptoms during taper don't necessarily indicate need for lifelong medication
• They should report symptoms immediately so you can adjust the pace 4
• Never stop abruptly or skip doses 331

This collaborative, patient-centered approach with close monitoring optimizes safety and minimizes morbidity during discontinuation 4.